Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ohr Pharmaceutical has received a US patent for composition of matter for the lactate salt form of Squalamine and its delivery using any pharmaceutically acceptable carrier.
Subscribe to our email newsletter
Squalamine is a small molecule anti-angiogenic which is used in the treatment of wet-age related macular degeneration (AMD) and Oncology.
Ohr Pharmaceutical CEO Irach Taraporewala said all previous clinical trials with Squalamine for wet-AMD and Oncology used the lactate salt form which this composition of matter patent covers.
"The claims also provide additional coverage for pharmaceutical carriers such as Ohr’s recently announced topical eye drop formulation for wet-AMD," Taraporewala said.
Ohr chairman Ira Greenstein said this patent grant adds tremendous value and protection to their Squalamine programs as they progress into clinical efficacy trials for wet-AMD, and seek a partner for oncology applications.